Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
